WO2002060919A3 - Molecules with extended half-lives, compositions and uses thereof - Google Patents
Molecules with extended half-lives, compositions and uses thereof Download PDFInfo
- Publication number
- WO2002060919A3 WO2002060919A3 PCT/US2001/048432 US0148432W WO02060919A3 WO 2002060919 A3 WO2002060919 A3 WO 2002060919A3 US 0148432 W US0148432 W US 0148432W WO 02060919 A3 WO02060919 A3 WO 02060919A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecules
- lives
- compositions
- fcrn
- proteins
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 abstract 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19153658.0A EP3569610A3 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half lives, compositions and uses thereof |
EP01997063A EP1355919B1 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
AT01997063T ATE489395T1 (en) | 2000-12-12 | 2001-12-12 | MOLECULES WITH LONGER HALF-LIFE, COMPOSITIONS AND THEIR USE |
JP2002561487A JP4336498B2 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-life and compositions and uses thereof |
DE60143544T DE60143544D1 (en) | 2000-12-12 | 2001-12-12 | MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE |
DK01997063.1T DK1355919T3 (en) | 2000-12-12 | 2001-12-12 | Molecules with longer half-lives, compositions and uses thereof |
EP10010679.8A EP2341060B1 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
AU2002248184A AU2002248184C1 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
CA2431600A CA2431600C (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
AU2008201419A AU2008201419C1 (en) | 2000-12-12 | 2008-03-27 | Molecules with extended half-lives, compositions and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25488400P | 2000-12-12 | 2000-12-12 | |
US60/254,884 | 2000-12-12 | ||
US28976001P | 2001-05-09 | 2001-05-09 | |
US60/289,760 | 2001-05-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002060919A2 WO2002060919A2 (en) | 2002-08-08 |
WO2002060919A9 WO2002060919A9 (en) | 2003-01-03 |
WO2002060919A3 true WO2002060919A3 (en) | 2003-09-04 |
Family
ID=26944296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/048432 WO2002060919A2 (en) | 2000-12-12 | 2001-12-12 | Molecules with extended half-lives, compositions and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (8) | US7083784B2 (en) |
EP (5) | EP2341060B1 (en) |
JP (7) | JP4336498B2 (en) |
AT (1) | ATE489395T1 (en) |
AU (1) | AU2002248184C1 (en) |
CA (1) | CA2431600C (en) |
CY (1) | CY1111283T1 (en) |
DE (1) | DE60143544D1 (en) |
DK (1) | DK1355919T3 (en) |
ES (2) | ES2727425T3 (en) |
PT (1) | PT1355919E (en) |
WO (1) | WO2002060919A2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8937158B2 (en) | 2003-03-03 | 2015-01-20 | Xencor, Inc. | Fc variants with increased affinity for FcγRIIc |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
Families Citing this family (746)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000042072A2 (en) * | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU785038B2 (en) * | 2000-01-27 | 2006-08-31 | Applied Molecular Evolution, Inc. | Ultra high affinity neutralizing antibodies |
EP2341074A1 (en) * | 2000-03-01 | 2011-07-06 | MedImmune, LLC | Antibodies binding to the f protein of a respiratory syncytial virus (rsv) |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP2341060B1 (en) * | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20080254027A1 (en) * | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20070148171A1 (en) * | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
US20050152899A1 (en) * | 2002-05-10 | 2005-07-14 | Kinch Michael S. | EphA2 agonistic monoclonal antibodies and methods of use thereof |
JP4557714B2 (en) * | 2002-05-10 | 2010-10-06 | メディミューン,エルエルシー | EphA2 monoclonal antibody and method of use thereof |
AU2003276832A1 (en) * | 2002-05-10 | 2004-02-25 | Medimmune, Llc | EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DK1562972T3 (en) * | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modification of FcRn binding affinities or serum half-lives for antibodies by mutagenesis |
EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7700100B2 (en) | 2003-01-13 | 2010-04-20 | Macrogenics, Inc. | FcγRIIB fusion proteins and compositions thereof |
JP4685764B2 (en) * | 2003-04-10 | 2011-05-18 | アボット バイオセラピューティクス コーポレイション | Modification of antibody FcRn binding affinity or serum half-life by mutagenesis |
ES2391087T3 (en) * | 2003-04-11 | 2012-11-21 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
CA2521594A1 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2 and non-neoplastic hyperproliferative cell disorders |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
JP4667383B2 (en) * | 2003-06-13 | 2011-04-13 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Aglycosyl anti-CD154 (CD40 ligand) antibody and use thereof |
JP4178514B2 (en) * | 2003-06-27 | 2008-11-12 | 東洋紡績株式会社 | Antibody screening method |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
DK2520654T3 (en) * | 2003-08-26 | 2017-05-01 | Univ Colorado Regents | Inhibitors of serine protease activity and their use in methods and compositions for the treatment of bacterial infections |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
US7276585B2 (en) * | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
US7691379B2 (en) | 2004-04-12 | 2010-04-06 | Medimmune, Llc | Anti-IL-9 antibody formulations |
NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
RS20070027A (en) | 2004-07-26 | 2008-11-28 | Biogen Idec Ma Inc., | Anti-cd154 antibodies |
PL2213683T3 (en) | 2004-08-04 | 2013-10-31 | Mentrik Biotech Llc | Variant Fc regions |
US7659374B2 (en) * | 2004-08-16 | 2010-02-09 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
KR20080080675A (en) * | 2004-08-19 | 2008-09-04 | 제넨테크, 인크. | Polypeptide variants with altered effector function |
US20060074225A1 (en) * | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | Methods of preventing and treating rsv infections and related conditions |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
JP4937138B2 (en) | 2005-01-05 | 2012-05-23 | エフ−シュタール・ビオテヒノロギシェ・フォルシュングス−ウント・エントヴィックルングスゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Synthetic immunoglobulin domains with binding properties designed in a region of the molecule that is different from the complementarity-determining region |
US20060275282A1 (en) * | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
SI1853631T1 (en) * | 2005-01-24 | 2016-04-29 | Board Of Regents, The University Of Texas System | Fc FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC USE |
PT1853718E (en) | 2005-02-15 | 2015-11-12 | Univ Duke | Anti-cd19 antibodies and uses in oncology |
WO2006130201A1 (en) | 2005-03-14 | 2006-12-07 | Board Of Regents, The University Of Texas System | Antigene oligomers inhibit transcription |
TWI671403B (en) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | Method for controlling controlled assembly of polypeptide |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
AU2006236439B2 (en) | 2005-04-15 | 2012-05-03 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP1874816A4 (en) | 2005-04-26 | 2010-08-25 | Medimmune Inc | Modulation of antibody effector function by hinge domain engineering |
JP5047947B2 (en) | 2005-05-05 | 2012-10-10 | デューク ユニバーシティ | Anti-CD19 antibody treatment for autoimmune disease |
BRPI0611069A2 (en) | 2005-05-06 | 2010-11-09 | Zymogenetics Inc | monoclonal antibody, humanized antibody, antibody fragment, use of an antagonist, and hybridoma |
US8163881B2 (en) * | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
AU2006265936A1 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Llc | An integrated approach for generating multidomain protein therapeutics |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
LT2573114T (en) | 2005-08-10 | 2016-10-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7790655B2 (en) | 2005-10-14 | 2010-09-07 | Medimmune, Llc | Cell display of antibody libraries |
ES2577292T3 (en) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Binding polypeptides with diversified VH / VL hypervariable sequences and consensus |
EP2641970B1 (en) | 2005-11-17 | 2014-12-24 | Board of Regents, The University of Texas System | Modulation of gene expression by oligomers targeted to chromosomal DNA |
US10155816B2 (en) * | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
PT1963369E (en) | 2005-11-28 | 2013-05-28 | Zymogenetics Inc | Il-21 antagonists |
RU2470941C2 (en) | 2005-12-02 | 2012-12-27 | Дженентек, Инк. | Binding polypeptides and use thereof |
EP1988922A4 (en) * | 2006-02-03 | 2010-06-02 | Medimmune Llc | Protein formulations |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
JP5144499B2 (en) * | 2006-03-31 | 2013-02-13 | 中外製薬株式会社 | Antibody modification method for purifying bispecific antibodies |
EP3056568B1 (en) * | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
KR101454508B1 (en) | 2006-05-30 | 2014-11-04 | 제넨테크, 인크. | Antibodies and immunoconjugates and uses therefor |
WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
AU2007281876B2 (en) | 2006-06-26 | 2013-09-05 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
AT503902B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING IMMUNE LOBULINS |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
AT503861B1 (en) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | METHOD FOR MANIPULATING T-CELL RECEPTORS |
CL2007002225A1 (en) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A |
JP5362563B2 (en) | 2006-08-03 | 2013-12-11 | アストラゼネカ・アクチエボラーグ | Antibodies against αVβ6 and uses thereof |
PT2511301T (en) | 2006-08-04 | 2018-03-08 | Medimmune Ltd | Human antibodies to erbb 2 |
US8466262B2 (en) | 2006-09-01 | 2013-06-18 | Zymogenetics, Inc. | Variable region sequences of IL-31 monoclonal antibodies and methods of use |
ES2383710T3 (en) | 2006-09-08 | 2012-06-25 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in the treatment of tumors, transplants and autoimmune diseases |
EP2407548A1 (en) * | 2006-10-16 | 2012-01-18 | MedImmune, LLC | Molecules with reduced half-lives, compositions and uses thereof |
WO2008052187A2 (en) | 2006-10-27 | 2008-05-02 | Genentech. Inc. | Antibodies and immunoconjugates and uses therefor |
CN101678100A (en) | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | methods of treating systemic lupus erythematosus |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
AU2007333735A1 (en) | 2006-12-19 | 2008-06-26 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
CA2679986C (en) | 2007-03-08 | 2018-03-06 | Martin Lackmann | Epha3 antibodies for the treatment of solid tumors |
EP1980269A1 (en) * | 2007-04-13 | 2008-10-15 | Katholieke Universiteit Leuven | Prevention of staphylococcus biofilm formation |
EP2737907A3 (en) | 2007-05-07 | 2014-11-05 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
EP1997830A1 (en) * | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US7580304B2 (en) * | 2007-06-15 | 2009-08-25 | United Memories, Inc. | Multiple bus charge sharing |
JP5602625B2 (en) | 2007-06-26 | 2014-10-08 | エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング | Binding substance display |
US20110077383A1 (en) * | 2007-07-03 | 2011-03-31 | Medimmune, Llc | Hinge domain engineering |
CN101952312A (en) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | Multispecific epitope binding proteins and uses thereof |
PE20120259A1 (en) | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | ANTI-CD37 ANTIBODIES |
CA2694364C (en) * | 2007-08-21 | 2016-11-22 | Morphosys Ag | Improved methods for the formation of disulphide bonds |
DK3059246T3 (en) | 2007-09-26 | 2018-10-01 | Chugai Pharmaceutical Co Ltd | Modified constant region of an antibody |
ES2595638T3 (en) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Method to modify the isoelectric point of an antibody by replacing amino acids in a CDR |
EP2219452B1 (en) | 2007-11-05 | 2015-10-14 | MedImmune, LLC | Methods of treating scleroderma |
MX2010005104A (en) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Anti-vegf antibody compositions and methods. |
HUE036548T2 (en) | 2007-12-07 | 2018-08-28 | Zymogenetics Inc | Humanized antibody molecules specific for IL-31 |
JP5745274B2 (en) | 2007-12-07 | 2015-07-08 | ザイモジェネティクス, インコーポレイテッド | Anti-human IL-21 monoclonal antibody |
US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
MX2010006735A (en) | 2007-12-21 | 2010-09-30 | Medimmune Ltd | Binding members for interleukin-4 receptor alpha (il-4rî±) - 173. |
US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
EP2808343B8 (en) * | 2007-12-26 | 2020-01-15 | Xencor, Inc. | Fc variants with altered binding to FcRn |
AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
EP2080770A1 (en) * | 2008-01-21 | 2009-07-22 | MorphoSys AG | Proteinaceous binding molecules comprising purification tags |
MX2010008578A (en) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity. |
MX2010010737A (en) | 2008-04-02 | 2010-12-20 | Macrogenics Inc | Her2/neu-specific antibodies and methods of using same. |
CN102046655B (en) | 2008-04-02 | 2016-09-14 | 宏观基因有限公司 | BCR-complex-specific antibody and its using method |
NZ602884A (en) | 2008-04-11 | 2014-08-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2280997A2 (en) * | 2008-04-18 | 2011-02-09 | Xencor, Inc. | Human equivalent monoclonal antibodies engineered from nonhuman variable regions |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
WO2010009129A2 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Methods of treating autoimmune diseases using cd4 antibodies |
KR20110057244A (en) | 2008-09-19 | 2011-05-31 | 메디뮨 엘엘씨 | Antibodies directed to dll4 and uses thereof |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
SG195558A1 (en) * | 2008-10-14 | 2013-12-30 | Genentech Inc | Immunoglobulin variants and uses thereof |
US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
CA2744158A1 (en) | 2008-11-22 | 2010-05-27 | Genentech, Inc. | Anti-angiogenesis therapy for the treatment of breast cancer |
EP2373689A1 (en) | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
WO2010078526A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
AU2010208125B2 (en) * | 2009-01-29 | 2015-02-12 | Medimmune, Llc | Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
JP5876728B2 (en) | 2009-03-06 | 2016-03-02 | カロバイオス ファーマシューティカルズ インコーポレイティッド | Method for treating leukemia and chronic myeloproliferative disease using antibody against EphA3 |
BRPI1008971A2 (en) | 2009-03-09 | 2016-03-15 | Bioatla Llc | methods for preparing a conditionally active biological protein, and a conditionally active biological response modifier, conditionally active biological protein, and pharmaceutical composition |
MA33194B1 (en) | 2009-03-16 | 2012-04-02 | Cephalon Australia Pty Ltd | HUMANIZED ANTIBODIES HAVING ANTITUMOR ACTIVITY |
JP5717624B2 (en) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | Antibody constant region variants |
EP3674317A1 (en) | 2009-03-19 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
BRPI1006448B1 (en) | 2009-03-25 | 2021-08-17 | Genentech, Inc | ANTI-FGFR3 ANTAGONIST ANTIBODY, MONOCLONAL ANTIBODY, POLYNUCLEOTIDE, VECTOR, TRANSGENIC MICROORGANISM, METHOD FOR THE PRODUCTION OF AN ANTI-FGFR3 ANTIBODY, PHARMACEUTICAL FORMULATION AND USES OF ANTI-FR3 ANTAGONIST ANTIBODY |
AP2011005984A0 (en) | 2009-04-20 | 2011-12-31 | Oxford Biotherapeutics Ltd | Antibodies specific to cadherin-17. |
US20120134984A1 (en) * | 2009-06-01 | 2012-05-31 | Olga Lubman | Molecules with extended half-lives and uses thereof |
RU2012101999A (en) | 2009-06-22 | 2013-07-27 | МЕДИММЬЮН, ЭлЭлСи | Fc RECOMBINED SITES FOR SITE-SPECIFIC CONJUGATION |
JP5762408B2 (en) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | Antibodies against human respiratory syncytial virus (RSV) and methods of use |
AU2010282340B2 (en) | 2009-08-13 | 2016-12-22 | The Johns Hopkins University | Methods of modulating immune function |
SG178419A1 (en) | 2009-08-15 | 2012-04-27 | Genentech Inc | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
EP3222287A1 (en) | 2009-08-24 | 2017-09-27 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
IN2012DN03025A (en) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
EP2481752B1 (en) | 2009-09-24 | 2016-11-09 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
TR201804897T4 (en) | 2009-10-07 | 2018-06-21 | Macrogenics Inc | POLYPEPTIDES CONTAINING FC REGION WITH ADVANCED EFFECTOR FUNCTION DUE TO CHANGES OF FUCOSILATION SIZE AND METHODS FOR THEIR USE |
EP2470569A1 (en) | 2009-10-13 | 2012-07-04 | Oxford Biotherapeutics Ltd. | Antibodies against epha10 |
CN102666589B (en) | 2009-10-14 | 2014-08-20 | 卡罗拜奥斯制药公司 | Antibodies to epha3 |
MX2012004647A (en) | 2009-10-22 | 2012-06-19 | Genentech Inc | Anti-hepsin antibodies and methods using same. |
PT2496691T (en) | 2009-11-02 | 2017-05-31 | Univ Washington | Therapeutic nuclease compositions and methods |
JP6007420B2 (en) | 2009-11-04 | 2016-10-12 | ファブラス エルエルシー | Antibody optimization method based on affinity maturation |
EP2496257A4 (en) | 2009-11-05 | 2013-02-27 | Cephalon Australia Pty Ltd | Treatment of cancer involving mutated kras or braf genes |
BR112012010153B1 (en) | 2009-11-05 | 2022-05-03 | Genentech, Inc | Method of producing an antibody |
US8881354B2 (en) | 2009-11-16 | 2014-11-11 | Jtekt Corporation | Tool radius adjusting system for boring holder, tool radius adjusting method in machine tool, and machine tool |
PT2504364T (en) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Targeted binding agents against b7-h1 |
JP5944831B2 (en) | 2009-12-23 | 2016-07-05 | シュニムネ ゲーエムベーハーSYNIMMUNE GmbH | Anti-FLT3 antibody and method of use thereof |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
MX2012008085A (en) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Notch1 binding agents and methods of use thereof. |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
KR20130009760A (en) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Cd20 antibodies and uses thereof |
WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
KR20180028561A (en) | 2010-02-23 | 2018-03-16 | 제넨테크, 인크. | Anti-angiogenesis therapy for the treatment of ovarian cancer |
CN103805202B (en) | 2010-02-25 | 2018-05-18 | 旭化成株式会社 | Copper oxide etching solution and use its engraving method |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
SG10201604336VA (en) | 2010-03-04 | 2016-07-28 | Macrogenics Inc | Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof |
US10435458B2 (en) | 2010-03-04 | 2019-10-08 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variants with reduced Fcgammar binding |
ES2550060T3 (en) | 2010-03-12 | 2015-11-04 | Abbvie Biotherapeutics Inc. | CTLA4 proteins and their uses |
TWI667346B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
MX340696B (en) | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies. |
EP2576616A4 (en) | 2010-05-27 | 2014-05-21 | Merck Sharp & Dohme | Method for preparing antibodies having improved properties |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
MY191929A (en) | 2010-06-03 | 2022-07-18 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
NZ602840A (en) | 2010-06-03 | 2014-11-28 | Genentech Inc | Immuno-pet imaging of antibodies and immunoconjugates and uses therefor |
JP2013533243A (en) | 2010-06-22 | 2013-08-22 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレート | Antibody to C3d fragment of complement component 3 |
NZ605400A (en) | 2010-07-09 | 2015-05-29 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
CN103097412B (en) | 2010-07-09 | 2016-08-10 | 克鲁塞尔荷兰公司 | Anti-human respiratory syncytial virus (RSV) antibody and using method |
AU2011282476B2 (en) | 2010-07-20 | 2015-08-20 | Cephalon Australia Pty Ltd | Anti-IL-23 heterodimer specific antibodies |
CN103261225A (en) | 2010-07-23 | 2013-08-21 | 波士顿大学董事会 | Anti-desupr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
CA2806438C (en) | 2010-07-29 | 2021-04-13 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
MX339622B (en) | 2010-08-02 | 2016-06-02 | Macrogenics Inc | Covalent diabodies and uses thereof. |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
EP2603526A1 (en) | 2010-08-13 | 2013-06-19 | Medimmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
CA2809369A1 (en) | 2010-08-27 | 2012-03-01 | Stem Centrx, Inc. | Notum protein modulators and methods of use |
NZ608814A (en) | 2010-09-03 | 2015-06-26 | Stem Centrx Inc | Novel modulators and methods of use |
EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
UA112062C2 (en) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | CD33-Binding Agent |
SG189322A1 (en) | 2010-10-13 | 2013-05-31 | Janssen Biotech Inc | Human oncostatin m antibodies and methods of use |
MX352929B (en) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | Stable heterodimeric antibody design with mutations in the fc domain. |
TW201631153A (en) | 2010-11-17 | 2016-09-01 | 中外製藥股份有限公司 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
DK2643352T3 (en) | 2010-11-23 | 2018-07-30 | Glaxo Group Ltd | Antigen Binding Proteins for Oncostatin M (OSM) |
EP2853542A1 (en) | 2010-11-24 | 2015-04-01 | Glaxo Group Limited | Multispecific antigen binding proteins targeting HGF |
BR112013013311A2 (en) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | cytotoxicity-inducing therapeutic agent |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
SG191081A1 (en) | 2010-12-08 | 2013-07-31 | Stem Centrx Inc | Novel modulators and methods of use |
CN103429261A (en) * | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | Modified antibody with improved half-life |
JOP20210044A1 (en) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
AR085141A1 (en) | 2011-02-03 | 2013-09-11 | Alexion Pharma Inc | A METHOD FOR EXTENDING THE SURVIVAL OF A RENAL PAD, USE OF AN ANTIBODY ANTI-CD200 TO EXTEND THE SURVIVAL OF PADS |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
RU2620065C2 (en) | 2011-02-08 | 2017-05-22 | МЕДИММЬЮН, ЭлЭлСи | Antibodies for specific binding of staphylococcus aureus alpha-toxin and methods of application |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
MX352889B (en) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Fcîriib-specific fc antibody. |
MY163539A (en) | 2011-03-29 | 2017-09-15 | Roche Glycart Ag | Antibody fc variants |
KR20140031217A (en) | 2011-04-20 | 2014-03-12 | 로슈 글리카트 아게 | Method and constructs for the ph dependent passage of the blood-brain-barrier |
US10654916B2 (en) | 2011-04-21 | 2020-05-19 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
LT2704737T (en) | 2011-04-29 | 2018-06-11 | University Of Washington | Therapeutic nuclease compositions and methods |
JP6145088B2 (en) | 2011-05-21 | 2017-06-07 | マクロジェニクス,インコーポレーテッド | Deimmunized serum binding domain and its use to extend serum half-life |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
EP2714732A4 (en) | 2011-05-25 | 2014-12-10 | Merck Sharp & Dohme | METHOD FOR PREPARING Fc-CONTAINING POLYPEPTIDES HAVING IMPROVED PROPERTIES |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
EP3527218A1 (en) | 2011-06-10 | 2019-08-21 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
HUE038509T2 (en) | 2011-06-10 | 2018-10-29 | Medimmune Ltd | Anti-pseudomonas psl binding molecules and uses thereof |
MX343580B (en) | 2011-06-13 | 2016-11-10 | Csl Ltd | Antibodies against g-csfr and uses thereof. |
WO2012178102A2 (en) | 2011-06-24 | 2012-12-27 | The Regents Of The Unversity Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
EA031181B1 (en) | 2011-06-28 | 2018-11-30 | Оксфорд Байотерепьютикс Лтд. | Antibody or an antigen binding fragment thereof that specifically binds to bst1, nucleic acids encoding chains thereof, host cell and method provided for making this antibody and use thereof for treating cancer and inflammatory diseases |
RU2639526C2 (en) * | 2011-06-28 | 2017-12-21 | ИНХИБРКС ЭлЭлСи | Fusion polypeptide containing wap domain and their application methods |
PT2726092T (en) | 2011-06-28 | 2019-10-08 | Lp Inhibrx | Serpin fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
UA117901C2 (en) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Antibody variants and uses thereof |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
WO2013012747A1 (en) | 2011-07-15 | 2013-01-24 | Oncomed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
GB201112429D0 (en) | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
WO2013014092A1 (en) | 2011-07-22 | 2013-01-31 | Csl Behring Gmbh | Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
EP2736925A2 (en) | 2011-07-27 | 2014-06-04 | Glaxo Group Limited | Anti-vegf single variable domains fused to fc domains |
WO2013019652A1 (en) | 2011-07-29 | 2013-02-07 | Eleven Biotherapeutics, Inc. | Purified proteins |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
UY34317A (en) | 2011-09-12 | 2013-02-28 | Genzyme Corp | T cell antireceptor antibody (alpha) / ß |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
HUE061002T2 (en) | 2011-09-23 | 2023-04-28 | Mereo Biopharma 5 Inc | Vegf/dll4 binding agents and uses thereof |
TW201817745A (en) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
CA3186128A1 (en) | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
EP3495389A1 (en) | 2011-09-30 | 2019-06-12 | Teva Pharmaceuticals Australia Pty Ltd | Antibodies against tl1a and uses thereof |
CN110627902A (en) | 2011-09-30 | 2019-12-31 | 中外制药株式会社 | Antigen binding molecules that induce an immune response against a target antigen |
EP2765192A4 (en) | 2011-10-05 | 2015-04-15 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain |
BR112014008804A2 (en) | 2011-10-11 | 2017-06-13 | Medimmune Llc | cd40l-specific tn3-derived carriers and methods of use |
PE20191242A1 (en) | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | ANTIBODY FORMULATIONS AND METHODS |
NZ756727A (en) | 2011-10-28 | 2022-12-23 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
EP2773667A1 (en) | 2011-11-01 | 2014-09-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
AU2012332590B2 (en) | 2011-11-01 | 2016-10-20 | Bionomics, Inc. | Anti-GPR49 antibodies |
CN104053671A (en) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | Antibodies and methods of treating cancer |
US10598653B2 (en) | 2011-11-01 | 2020-03-24 | Bionomics Inc. | Methods of blocking cancer stem cell growth |
RU2675319C2 (en) | 2011-11-04 | 2018-12-18 | Займворкс Инк. | STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN Fc DOMAIN |
WO2013070615A1 (en) | 2011-11-07 | 2013-05-16 | Medlmmune, Llc. | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
CN103906533A (en) | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | Multispecific and multivalent binding proteins and uses thereof |
WO2013074598A1 (en) * | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
KR102080535B1 (en) | 2011-11-23 | 2020-02-24 | 메디뮨 엘엘씨 | Binding molecules specific for her3 and uses thereof |
KR20230143201A (en) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | Drug containing carrier into cell for forming immune complex |
ES2784131T3 (en) | 2011-12-05 | 2020-09-22 | X Body Inc | PDGF receptor beta-binding polypeptides |
AU2012355415B2 (en) | 2011-12-20 | 2017-07-06 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
SG11201403444UA (en) * | 2011-12-21 | 2014-07-30 | Amgen Inc | Variant fc-polypeptides with enhanced binding to the neonatal fc receptor |
WO2013096948A1 (en) | 2011-12-23 | 2013-06-27 | Lydon Nicholas B | Immunoglobulins and variants directed against pathogenic microbes |
EP3539982A3 (en) | 2011-12-23 | 2020-01-15 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
KR102041412B1 (en) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | Derivatives of Immunglobulin Fc fragment |
AU2013202648B2 (en) | 2012-01-10 | 2016-05-19 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
LT2804623T (en) | 2012-01-12 | 2019-12-10 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
CN113480639A (en) * | 2012-02-09 | 2021-10-08 | 中外制药株式会社 | Fc region variants of antibodies |
ES2771208T3 (en) | 2012-02-15 | 2020-07-06 | Bioverativ Therapeutics Inc | Factor VIII compositions and methods of preparation and use thereof |
DK2822577T3 (en) | 2012-02-15 | 2019-04-01 | Bioverativ Therapeutics Inc | RECOMBINANT FACTOR VIII PROTEINS |
TWI682939B (en) | 2012-02-24 | 2020-01-21 | 日商中外製藥股份有限公司 | Antigen-binding molecule that promotes antigen disappearance via FcγRIIB |
CN104520324A (en) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | DLL3 modulators and methods of use |
US9376494B2 (en) | 2012-03-28 | 2016-06-28 | Sanofi | Antibodies to kallidin and des-Arg9-kallidin |
WO2013155346A1 (en) | 2012-04-11 | 2013-10-17 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
WO2013165690A1 (en) * | 2012-04-30 | 2013-11-07 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
WO2013169657A1 (en) | 2012-05-07 | 2013-11-14 | Sanofi | Methods for preventing biofilm formation |
AU2013258834B2 (en) | 2012-05-10 | 2017-09-07 | Zymeworks Bc Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain |
GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
CN104487457B (en) | 2012-05-30 | 2018-01-26 | 中外制药株式会社 | Target tissue specific antigen binding molecule |
EP3892638A1 (en) | 2012-05-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
WO2013184912A2 (en) | 2012-06-06 | 2013-12-12 | Oncomed Pharmaceuticals, Inc. | Binding agents that modulate the hippo pathway and uses thereof |
AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | Chimeric clotting factors |
US9499634B2 (en) | 2012-06-25 | 2016-11-22 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
EA201792485A3 (en) | 2012-07-11 | 2019-03-29 | Амуникс Оперэйтинг Инк. | COMPLEX OF FACTOR VIII WITH XTEN AND PROTEIN FACTOR VILLEBRAND VON AND ITS APPLICATION (OPTIONS) |
CA2874554C (en) | 2012-07-13 | 2019-12-03 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
KR20150032340A (en) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
DK3381943T3 (en) | 2012-07-25 | 2022-05-16 | Celldex Therapeutics Inc | ANTI-KIT ANTIBODIES AND USES THEREOF |
WO2014029752A1 (en) | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
BR112015001955A2 (en) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | fcgamariib specific fc region variant |
WO2014030750A1 (en) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | MOUSE FcγRII-SPECIFIC Fc ANTIBODY |
EP3366705B1 (en) | 2012-09-12 | 2023-05-03 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
AR093788A1 (en) | 2012-12-04 | 2015-06-24 | Oncomed Pharm Inc | IMMUNOTHERAPY WITH LINK AGENTS |
AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
EP2935332B1 (en) | 2012-12-21 | 2021-11-10 | MedImmune, LLC | Anti-h7cr antibodies |
EA201500741A1 (en) | 2013-01-10 | 2016-01-29 | Генмаб Б.В. | HUMAN FG IGG1 OPTIONS AND THEIR APPLICATION |
CA2898262A1 (en) | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
ES2715710T3 (en) | 2013-01-25 | 2019-06-05 | Shire Human Genetic Therapies | Folistatin in the treatment of Duchenne muscular dystrophy |
DK2951208T3 (en) | 2013-02-01 | 2020-01-13 | Kira Biotech Pty Ltd | ANTI-CD83 ANTIBODIES AND USE THEREOF |
AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
PL2953971T3 (en) | 2013-02-07 | 2023-07-03 | Csl Limited | Il-11r binding proteins and uses thereof |
LT3889173T (en) | 2013-02-15 | 2023-10-10 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
TR201908761T4 (en) | 2013-02-22 | 2019-07-22 | Abbvie Stemcentrx Llc | Antidll3-antibody-pbd conjugates and their uses. |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
JP6636334B2 (en) | 2013-03-08 | 2020-01-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Treatment and prevention of remote ischemia-reperfusion injury |
CN105189555B (en) | 2013-03-11 | 2020-07-24 | 建新公司 | Highly glycosylated binding polypeptides |
JP6450364B2 (en) | 2013-03-13 | 2019-01-09 | セセン バイオ, インコーポレイテッド | Chimeric cytokine formulations for ocular delivery |
US20140271641A1 (en) * | 2013-03-14 | 2014-09-18 | University Of Guelph | Thrombospondin-1 polypeptides and methods of using same |
PL2968520T3 (en) | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
WO2014145000A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotherapeutics Inc. | Anti-cd25 antibodies and their uses |
EA038918B1 (en) | 2013-03-15 | 2021-11-09 | Зинджения, Инк. | Peptide binding an epidermal growth factor receptor, multispecific complexes comprising peptide and antibodies and use thereof |
US9260527B2 (en) | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
MX2015012563A (en) | 2013-03-15 | 2016-10-26 | Abbvie Biotechnology Ltd | Anti-cd25 antibodies and their uses. |
AU2014233528B2 (en) | 2013-03-15 | 2019-02-28 | Abbvie Biotherapeutics Inc. | Fc variants |
US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
ES2847383T3 (en) | 2013-03-15 | 2021-08-03 | Atyr Pharma Inc | Fc-histidyl-tRNA synthetase conjugates |
JP6224739B2 (en) | 2013-03-15 | 2017-11-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Anti-LAG-3 binding protein |
JP6387392B2 (en) | 2013-03-15 | 2018-09-05 | バイオベラティブ セラピューティクス インコーポレイテッド | Factor IX polypeptide preparation |
US11634502B2 (en) | 2013-03-15 | 2023-04-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
KR102318483B1 (en) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Fc region variant |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
DK3677591T3 (en) | 2013-04-29 | 2023-03-20 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
KR102293064B1 (en) | 2013-05-20 | 2021-08-23 | 제넨테크, 인크. | Anti-transferrin receptor antibodies and methods of use |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
EP3875106A1 (en) | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
TW201722994A (en) | 2013-08-13 | 2017-07-01 | 賽諾菲公司 | Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof |
CR20190319A (en) | 2013-08-13 | 2019-08-29 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
CN105848671B (en) | 2013-08-28 | 2019-12-13 | 艾伯维施特姆森特克斯有限责任公司 | Site-specific antibody conjugation methods and compositions |
WO2015031541A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Novel sez6 modulators and methods of use |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
RS63571B9 (en) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
US20160257748A1 (en) | 2013-09-25 | 2016-09-08 | Amgen Inc. | V-c-fc-v-c antibody |
EP3048899B1 (en) | 2013-09-25 | 2021-09-08 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
EP3050896B1 (en) | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
AU2014329609B2 (en) | 2013-10-02 | 2019-09-12 | Humabs Biomed Sa | Neutralizing anti-influenza A antibodies and uses thereof |
AU2014333563B9 (en) | 2013-10-11 | 2020-04-02 | Oxford Biotherapeutics Ltd | Conjugated antibodies against LY75 for the treatment of cancer |
WO2015066557A1 (en) | 2013-10-31 | 2015-05-07 | Resolve Therapeutics, Llc | Therapeutic nuclease molecules with altered glycosylation and methods |
RU2016122041A (en) | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | NEW ANTI-CLAUDIN ANTIBODIES AND WAYS OF THEIR APPLICATION |
EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
CA2966352A1 (en) * | 2013-11-26 | 2015-06-04 | The Brigham And Women's Hospital, Inc. | Compositions and methods for modulating an immune response |
MX2016007066A (en) | 2013-12-02 | 2016-09-08 | Oncomed Pharm Inc | Identification of predictive biomarkers associated with wnt pathway inhibitors. |
TW202043467A (en) | 2013-12-04 | 2020-12-01 | 日商中外製藥股份有限公司 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
CN105916519B (en) | 2013-12-09 | 2021-10-22 | 爱乐科斯公司 | anti-Siglec-8 antibodies and methods of use thereof |
EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
EA035324B1 (en) | 2013-12-24 | 2020-05-28 | Ардженкс Бвба | NEONATAL Fc RECEPTOR (FcRn) ANTAGONISTS AND METHODS OF USE THEREOF |
IL246476B (en) | 2014-01-10 | 2022-06-01 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
US10675352B2 (en) | 2014-02-14 | 2020-06-09 | Centrose, Llc | Extracellular targeted drug conjugates |
EP3110446B1 (en) | 2014-02-28 | 2021-12-01 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
US9738702B2 (en) * | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
ES2897765T3 (en) | 2014-03-14 | 2022-03-02 | Hoffmann La Roche | Methods and compositions for the secretion of heterologous polypeptides |
ES2940903T3 (en) | 2014-03-19 | 2023-05-12 | Genzyme Corp | Site-specific glycomanipulation of targeting residues |
EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
WO2015143271A1 (en) | 2014-03-21 | 2015-09-24 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
MX2016012873A (en) | 2014-04-04 | 2017-03-07 | Bionomics Inc | Humanized antibodies that bind lgr5. |
HUE051676T2 (en) | 2014-04-08 | 2021-03-29 | Boston Pharmaceuticals Inc | Binding molecules specific for il-21 and uses thereof |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
EP3888690A3 (en) | 2014-05-16 | 2021-10-20 | MedImmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
MA47849A (en) | 2014-05-28 | 2020-01-29 | Agenus Inc | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE |
BR112016025393A2 (en) * | 2014-06-12 | 2017-12-12 | Hoffmann La Roche | method for selecting an entire antibody, plurality of antibodies, use of one or more amino acid mutations and variant whole antibody |
EP3157945A4 (en) | 2014-06-20 | 2017-11-22 | F. Hoffmann-La Roche AG | Chagasin-based scaffold compositions, methods, and uses |
WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
KR102130600B1 (en) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics |
AU2015289805B2 (en) | 2014-07-15 | 2020-06-25 | Humabs Biomed Sa | Neutralizing anti-influenza B antibodies and uses thereof |
BR112017001385B1 (en) | 2014-07-22 | 2023-12-05 | Cb Therapeutics, Inc. | ISOLATED ANTIBODY OR FRAGMENT THEREOF THAT BINDS PD-1, USE OF IT, COMPOSITION, ISOLATED POLYNUCLEOTIDE AND EXPRESSION VECTOR |
EP3177649B1 (en) | 2014-08-05 | 2024-02-28 | Apollomics Inc. | Anti-pd-l1 antibodies |
CA2958018A1 (en) | 2014-08-11 | 2016-02-18 | University Of Massachusetts | Anti-ospa antibodies and methods of use |
TWI711629B (en) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | Compound targeting il-23a and tnf-alpha and uses thereof |
TW201617368A (en) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | Novel anti-MFI2 antibodies and methods of use |
JP2017529853A (en) | 2014-09-25 | 2017-10-12 | アムジエン・インコーポレーテツド | Bispecific protein that can be activated by proteases |
MA40764A (en) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
CR20170110A (en) | 2014-09-26 | 2017-05-08 | Bayer Pharma AG | STABILIZED DERIVATIVES OF ADRENOMEDULINE AND USE OF THE SAME |
AU2015323860B2 (en) | 2014-09-29 | 2021-05-27 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
CN113956361A (en) | 2014-10-01 | 2022-01-21 | 免疫医疗有限公司 | Antibodies to ticagrelor and methods of use thereof |
WO2016057769A2 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
ES2753391T3 (en) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Adenosine deaminase 2 (ADA2) compositions, variants thereof and methods of use thereof |
EP3209695A4 (en) | 2014-10-23 | 2018-05-30 | DendroCyte BioTech Pty Ltd | Cd83 binding proteins and uses thereof |
SG11201703251TA (en) | 2014-10-29 | 2017-05-30 | Teva Pharmaceuticals Australia Pty Ltd | INTERFERON α2B VARIANTS |
US20160130324A1 (en) | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
WO2016073789A2 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
CN107074966A (en) * | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | The Fc region variants of FCRN and albumin A binding property with change |
KR20170080607A (en) | 2014-11-10 | 2017-07-10 | 메디뮨 리미티드 | Binding molecules specific for cd73 and uses thereof |
EP3789403A1 (en) | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
ES2807182T3 (en) | 2014-11-21 | 2021-02-22 | Bristol Myers Squibb Co | CD73 Antibodies and Their Uses |
WO2016081746A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
US9382321B2 (en) | 2014-11-26 | 2016-07-05 | Adventis Health System/Sunbelt, Inc. | Effector-deficient anti-CD32A antibodies |
BR112017011234A2 (en) | 2014-12-10 | 2018-03-27 | Genentech Inc | antibodies to the blood-brain barrier receptor and methods of use |
CN107108726A (en) | 2014-12-19 | 2017-08-29 | 中外制药株式会社 | Anti-myostatin antibodies, the polypeptide comprising variant FC areas and application method |
WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
SG10201710322VA (en) | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
EP3237450B1 (en) | 2014-12-22 | 2021-03-03 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
WO2016106302A1 (en) | 2014-12-23 | 2016-06-30 | Bristol-Myers Squibb Company | Antibodies to tigit |
SG10201906471PA (en) | 2015-01-14 | 2019-09-27 | Brigham & Womens Hospital Inc | Treatment of cancer with anti-lap monoclonal antibodies |
JP2018506526A (en) | 2015-01-29 | 2018-03-08 | ボード オブ トラスティーズ オブ ミシガン ステイト ユニバーシティBoard Of Trustees Of Michigan State University | Cryptic polypeptides and uses thereof |
CN114773469A (en) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof |
WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
TW202339800A (en) | 2015-02-27 | 2023-10-16 | 日商中外製藥股份有限公司 | Composition for treating IL-6-related diseases |
LT3268391T (en) | 2015-03-09 | 2021-09-10 | Argenx Bvba | Methods of reducing serum levels of fc-containing agents using fcrn antagonsits |
HUE053097T2 (en) | 2015-03-31 | 2021-06-28 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
FR3034420A1 (en) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | ANTI-CD303 MONOCLONAL ANTIBODIES |
WO2016159213A1 (en) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | Method for producing polypeptide hetero-oligomer |
ES2936317T3 (en) | 2015-05-29 | 2023-03-16 | Bristol Myers Squibb Co | Antibodies against OX40 and uses thereof |
AU2016272045B2 (en) | 2015-06-04 | 2018-04-19 | Ospedale San Raffaele Srl | Inhibitor of IGFBP3/TMEM219 axis and diabetes |
CA2986080C (en) | 2015-06-04 | 2023-12-05 | Ospedale San Raffaele Srl | Inhibitor of igfbp3 for the treatment of intestinal disorders |
TWI790642B (en) | 2015-06-05 | 2023-01-21 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
EA201890162A1 (en) | 2015-06-29 | 2018-07-31 | Бристол-Маерс Сквибб Компани | ANTIBODIES TO CD40 WITH ENHANCED AGONISTIC ACTIVITY |
KR102644875B1 (en) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Compounds targeting IL-23A and B-cell activating factor (BAFF) and uses thereof |
SG10201906059VA (en) | 2015-07-30 | 2019-08-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
EP3888752A1 (en) | 2015-07-31 | 2021-10-06 | MedImmune Limited | Il-6 antibodies for use in treating cardiovascular diseases |
KR20180029262A (en) | 2015-08-03 | 2018-03-20 | 바이오버라티브 테라퓨틱스 인크. | Factor IX fusion proteins and methods for their manufacture and use |
WO2017040790A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
EP3344654B1 (en) | 2015-09-02 | 2020-10-21 | Immutep S.A.S. | Anti-lag-3 antibodies |
US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
TWI799366B (en) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | Cystine knot scaffold platform |
TWI703158B (en) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | Antibodies that specifically bind to tl1a |
CA2999160A1 (en) | 2015-09-23 | 2017-03-30 | Oncomed Pharmaceuticals, Inc. | Methods and compositions for treatment of cancer |
UA126549C2 (en) | 2015-10-01 | 2022-11-02 | Хіт Байолоджикс, Інк. | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
KR20180084772A (en) | 2015-10-08 | 2018-07-25 | 마크로제닉스, 인크. | Combination Therapy for Cancer Treatment |
MX2018004474A (en) | 2015-10-12 | 2018-11-09 | Aprogen Kic Inc | Anti-cd43 antibody and use thereof for cancer treatment. |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
WO2017083451A1 (en) | 2015-11-10 | 2017-05-18 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
AU2016365117A1 (en) | 2015-11-30 | 2018-05-31 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
AU2016365114A1 (en) | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
JP7089470B2 (en) | 2015-12-02 | 2022-06-22 | アジェナス インコーポレイテッド | Antibodies and how to use them |
EA201891178A1 (en) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
AU2016381992B2 (en) | 2015-12-28 | 2024-01-04 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
RU2739208C2 (en) | 2015-12-31 | 2020-12-21 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Anti-pcsk9 antibody, its antigen-binding domain and medical application thereof |
WO2017118307A1 (en) | 2016-01-05 | 2017-07-13 | 江苏恒瑞医药股份有限公司 | Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof |
AU2017214378B2 (en) | 2016-02-01 | 2023-05-04 | Bioverativ Therapeutics Inc. | Optimized Factor VIII genes |
UY37127A (en) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME |
CN116063494A (en) | 2016-03-04 | 2023-05-05 | 洛克菲勒大学 | Antibodies to CD40 with enhanced agonist activity |
MX2018010473A (en) | 2016-03-04 | 2018-09-28 | Squibb Bristol Myers Co | Combination therapy with anti-cd73 antibodies. |
MX2018010470A (en) | 2016-03-04 | 2018-12-06 | Shire Human Genetic Therapies | Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy. |
SG11201807936VA (en) | 2016-03-14 | 2018-10-30 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
KR20180138205A (en) | 2016-03-22 | 2018-12-28 | 바이오노믹스 리미티드 | Administration of anti-LGR5 monoclonal antibody |
MA45473A (en) | 2016-04-04 | 2019-02-13 | Shire Human Genetic Therapies | CONJUGATE C1 ESTERASE INHIBITOR AND ITS USES |
CR20180529A (en) | 2016-04-04 | 2019-03-21 | Bioverativ Usa Inc | ANTI-FACTOR ANTIBODIES BB OF THE COMPLEMENT AND USES OF THESE CROSSED REFERENCES |
JP7002467B2 (en) | 2016-04-15 | 2022-01-20 | マクロジェニクス,インコーポレーテッド | New B7-H3 binding molecule, its antibody drug conjugate, and how to use it |
JP2019522960A (en) | 2016-04-21 | 2019-08-22 | アッヴィ・ステムセントルクス・エル・エル・シー | Novel anti-BMPR1B antibody and method of use |
MX2018014387A (en) | 2016-05-27 | 2019-03-14 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof. |
US11365256B2 (en) | 2016-06-08 | 2022-06-21 | Xencor, Inc. | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases |
US20190169280A1 (en) | 2016-06-30 | 2019-06-06 | Prothena Biosciences Limited | Compositions for treating amyloidosis |
EP3478830B1 (en) | 2016-07-01 | 2024-04-10 | Resolve Therapeutics, LLC | Optimized binuclease fusions and methods |
EP3481393B1 (en) | 2016-07-05 | 2021-04-14 | Beigene, Ltd. | Combination of a pd-1 antagonist and a raf inhibitor for treating cancer |
MA45602A (en) | 2016-07-08 | 2019-05-15 | Staten Biotechnology B V | ANTI-APOC3 ANTIBODIES AND THEIR METHODS OF USE |
CA3030834A1 (en) | 2016-07-15 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
CA3030926A1 (en) | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd47 combination therapy |
US11858980B2 (en) | 2016-08-02 | 2024-01-02 | Visterra, Inc. | Engineered polypeptides and uses thereof |
CN116271014A (en) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | Compositions for preventing or treating IL-8 related diseases |
WO2018027124A1 (en) | 2016-08-05 | 2018-02-08 | Medimmune, Llc | Anti-o2 antibodies and uses thereof |
US20210332112A1 (en) * | 2016-08-15 | 2021-10-28 | Board Of Regents, The University Of Texas System | Stabilized pertussis antibodies with extended half-life |
US10538579B2 (en) | 2016-08-15 | 2020-01-21 | Board Of Regents, The University Of Texas System | Bispecific pertussis antibodies |
US11701357B2 (en) | 2016-08-19 | 2023-07-18 | Beigene Switzerland Gmbh | Treatment of B cell cancers using a combination comprising Btk inhibitors |
JP2019534858A (en) | 2016-09-09 | 2019-12-05 | ジェネンテック, インコーポレイテッド | Selective peptide inhibitor of FRIZZLED |
EP3512883A1 (en) | 2016-09-13 | 2019-07-24 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
AU2017343621B2 (en) | 2016-10-11 | 2021-12-02 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
EP3529273A4 (en) | 2016-10-19 | 2020-07-01 | Medlmmune, LLC | Anti-o1 antibodies and uses thereof |
TW202300515A (en) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | Anti-chikv antibodies and uses thereof |
SG11201903287PA (en) | 2016-10-21 | 2019-05-30 | Adimab Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
WO2018075954A2 (en) | 2016-10-21 | 2018-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
JP2020503843A (en) | 2016-10-21 | 2020-02-06 | アディマブ, エルエルシー | Anti-respiratory syncytial virus antibodies and methods for their production and use |
TWI788307B (en) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
EP3548063A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
WO2018104893A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
SI3551660T1 (en) | 2016-12-07 | 2024-02-29 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
AU2017373889A1 (en) | 2016-12-07 | 2019-06-06 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
EP3551225A1 (en) | 2016-12-07 | 2019-10-16 | Agenus Inc. | Antibodies and methods of use thereof |
JP7155126B2 (en) | 2016-12-21 | 2022-10-18 | セファロン インコーポレイテッド | Antibody that specifically binds to human IL-15 and use thereof |
JP7128819B2 (en) | 2016-12-23 | 2022-08-31 | マクロジェニクス,インコーポレーテッド | ADAM9 binding molecules, and methods of use thereof |
SI3558391T1 (en) | 2016-12-23 | 2022-06-30 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
US20180230218A1 (en) | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
CA3049163A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
CN110536695A (en) | 2017-01-25 | 2019-12-03 | 分子模板公司 | Cell-targeting molecule including deimmunized shiga toxin A Effect of subunit and CD8+ t cell epitope |
JP2020505029A (en) * | 2017-01-25 | 2020-02-20 | メディミューン,エルエルシー | Relaxin fusion polypeptides and uses thereof |
TWI774726B (en) | 2017-01-25 | 2022-08-21 | 英屬開曼群島商百濟神州有限公司 | Crystalline forms of (s)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
JP2020506190A (en) | 2017-02-01 | 2020-02-27 | イェール ユニバーシティーYale University | Treatment of diuretic resistance |
CA3053774A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
FI3583120T3 (en) | 2017-02-17 | 2023-01-13 | Engineered transferrin receptor binding polypeptides | |
WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
JP7132232B2 (en) | 2017-02-24 | 2022-09-06 | マクロジェニクス,インコーポレーテッド | Bispecific binding molecules capable of binding CD137 and tumor antigens and uses thereof |
EP3585410B9 (en) | 2017-02-27 | 2023-10-04 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
CR20190417A (en) | 2017-03-16 | 2019-12-06 | Medimmune Ltd | Anti-par2 antibodies and uses thereof |
UY37651A (en) | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | IL-1R-I UNION POLYPEPTIDE |
TWI788340B (en) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | Anti-icos agonist antibodies and uses thereof |
AU2018253176B2 (en) | 2017-04-13 | 2023-02-02 | Agenus Inc. | Anti-CD137 antibodies and methods of use thereof |
WO2018192974A1 (en) | 2017-04-18 | 2018-10-25 | Université Libre de Bruxelles | Biomarkers and targets for proliferative diseases |
US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
CA3059133A1 (en) | 2017-04-21 | 2018-10-25 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
HRP20230941T1 (en) | 2017-05-01 | 2023-11-24 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
JP2020518638A (en) | 2017-05-05 | 2020-06-25 | アラコス インコーポレイテッド | Methods and compositions for treating allergic eye diseases |
WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
AU2018266202A1 (en) | 2017-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
US20180362604A1 (en) | 2017-05-12 | 2018-12-20 | Shire Human Genetic Therapies, Inc. | Recombinant Follistatin-FC Fusion Proteins and Use in Treating Duchenne Muscular Dystrophy |
JOP20190271A1 (en) * | 2017-05-24 | 2019-11-21 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use for immune related disorders |
BR112019024419A2 (en) | 2017-05-25 | 2020-07-14 | Bristol-Myers Squibb Company | antibodies comprising modified heavy constant regions |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN116271012A (en) | 2017-07-27 | 2023-06-23 | 瑞颂医药公司 | High concentration anti-C5 antibody formulations |
TW201920255A (en) | 2017-08-09 | 2019-06-01 | 美商生物化學醫療公司 | Nucleic acid molecules and uses thereof |
MX2020002070A (en) | 2017-08-22 | 2020-03-24 | Sanabio Llc | Soluble interferon receptors and uses thereof. |
EP3672990A1 (en) | 2017-08-25 | 2020-07-01 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
JP7039694B2 (en) | 2017-10-31 | 2022-03-22 | スターテン・バイオテクノロジー・ベー・フェー | Anti-APOC3 antibody and how to use it |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
US20210179721A1 (en) | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
CA3081144A1 (en) | 2017-12-08 | 2019-06-13 | Argenx Bvba | Use of fcrn antagonists for treatment of generalized myasthenia gravis |
WO2019118266A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
CA3085765A1 (en) | 2017-12-15 | 2019-06-20 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
US11306149B2 (en) | 2017-12-27 | 2022-04-19 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
FR3076294B1 (en) | 2017-12-29 | 2022-01-28 | Lab Francais Du Fractionnement | METHOD FOR PURIFYING ANTIBODIES FROM RAW MILK |
BR112020013519A2 (en) | 2018-01-05 | 2020-12-01 | Corvidia Therapeutics, Inc | method for treating an inflammation. |
WO2019139891A1 (en) | 2018-01-09 | 2019-07-18 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
MX2020007429A (en) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Subcutaneous dosing of anti-cd38 antibodies. |
BR112020015228A2 (en) | 2018-02-01 | 2020-12-29 | Bioverativ Therapeutics Inc. | USE OF LENTIVIRAL VECTORS THAT EXPRESS FACTOR VIII |
JP2021512962A (en) | 2018-02-13 | 2021-05-20 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expansion culture of tumor-infiltrating lymphocytes (TIL) with adenosine A2A receptor antagonist and therapeutic combination of TIL and adenosine A2A receptor antagonist |
US11512127B2 (en) | 2018-02-14 | 2022-11-29 | Viela Bio, Inc. | Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases |
BR112020016485A2 (en) | 2018-02-15 | 2020-12-15 | Macrogenics, Inc. | BINDING MOLECULE, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A DISEASE |
MA52416A (en) | 2018-03-02 | 2021-04-21 | Five Prime Therapeutics Inc | B7-H4 ANTIBODIES AND PROCESSES FOR USE |
KR20200132938A (en) | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | Anti-dengue virus antibodies with cross-reactivity against Zika virus and methods of use |
US11654184B2 (en) | 2018-03-20 | 2023-05-23 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
AU2019240111A1 (en) * | 2018-03-21 | 2020-09-17 | ALX Oncology Inc. | Antibodies against signal-regulatory protein alpha and methods of use |
CA3088676A1 (en) | 2018-03-23 | 2019-09-26 | Universite Libre De Bruxelles | Wnt signaling agonist molecules |
EP3774861A1 (en) | 2018-03-28 | 2021-02-17 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
AU2019244478A1 (en) | 2018-03-28 | 2020-11-12 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
BR112020023167A2 (en) | 2018-05-14 | 2021-02-09 | Werewolf Therapeutics, Inc. | activatable cytokine polypeptides and methods of using these |
CA3100007A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
KR20210013091A (en) | 2018-05-16 | 2021-02-03 | 시에스엘 리미티드 | Soluble complement receptor type 1 variant and uses thereof |
KR20210020030A (en) | 2018-05-18 | 2021-02-23 | 바이오버라티브 테라퓨틱스 인크. | How to treat hemophilia A |
KR20210027352A (en) | 2018-06-04 | 2021-03-10 | 바이오젠 엠에이 인코포레이티드 | Anti-VLA-4 antibody with reduced effector function |
TW202016151A (en) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | Multi-specific binding proteins for cancer treatment |
GB201809746D0 (en) | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
CA3102841A1 (en) | 2018-06-15 | 2019-12-19 | Proclara Biosciences, Inc. | General amyloid interaction motif (gaim) |
AU2019294510A1 (en) | 2018-06-26 | 2021-01-21 | Immunogen, Inc. | Immunoconjugates targeting ADAM9 and methods of use thereof |
BR112020026512A2 (en) | 2018-07-03 | 2021-04-06 | Bristol-Myers Squibb Company | FGF-21 FORMULATIONS |
WO2020014306A1 (en) | 2018-07-10 | 2020-01-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
CA3107126A1 (en) | 2018-07-19 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-bcma x anti-cd3 antibodies and uses thereof |
MX2021001599A (en) | 2018-08-09 | 2021-07-02 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof for non-viral gene therapy. |
CA3109346A1 (en) | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Combination therapies comprising sirp alpha-based chimeric proteins |
KR20210069639A (en) * | 2018-08-30 | 2021-06-11 | 에이치씨더블유 바이올로직스, 인크. | Single-chain chimeric polypeptides and uses thereof |
JP7449292B2 (en) | 2018-08-30 | 2024-03-13 | エイチシーダブリュー バイオロジックス インコーポレイテッド | Treatments for age-related disorders |
AU2019328290A1 (en) | 2018-08-30 | 2021-02-25 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
EP3844280A4 (en) * | 2018-08-31 | 2022-09-14 | Yale University | Enpp1 polypeptides and methods of using same |
TW202031273A (en) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | Treatment of nsclc patients refractory for anti-pd-1 antibody |
BR112021005907A2 (en) | 2018-09-27 | 2021-08-10 | Xilio Development, Inc. | masked cytokines, nucleic acid, vector, host cell, methods for producing a masked cytokine, for treating or preventing a neoplastic disease and for treating or preventing a neoplastic inflammatory or autoimmune disease, composition, pharmaceutical composition and kit |
CN112969503A (en) | 2018-10-03 | 2021-06-15 | 斯塔滕生物技术有限公司 | Antibodies specific for human and cynomolgus macaques APOC3 and methods of use thereof |
TW202029980A (en) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof |
US20230416385A1 (en) | 2018-11-01 | 2023-12-28 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
SG11202104663PA (en) | 2018-11-05 | 2021-06-29 | Iovance Biotherapeutics Inc | Treatment of nsclc patients refractory for anti-pd-1 antibody |
EP4257195A3 (en) | 2018-11-09 | 2024-01-03 | University of Massachusetts | Anti-cfae antibodies and methods of use |
JP2022509942A (en) | 2018-11-16 | 2022-01-25 | ブリストル-マイヤーズ スクイブ カンパニー | Anti-NKG2A antibody and its use |
KR20210096167A (en) | 2018-11-28 | 2021-08-04 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies Comprising Modified Heavy Chain Constant Regions |
CN113227134A (en) | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | Fc region variants of antibodies |
US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2020114616A1 (en) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
WO2020115281A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
WO2020115283A1 (en) | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
JP2022515770A (en) | 2018-12-21 | 2022-02-22 | カイマブ・リミテッド | FIXa x FX bispecific antibody with common light chain |
MX2021007768A (en) | 2018-12-26 | 2021-08-24 | Xilio Dev Inc | Anti-ctla4 antibodies and methods of use thereof. |
CN113227135A (en) | 2018-12-28 | 2021-08-06 | 斯帕克斯治疗公司 | Binding molecules specific for claudin 18.2, compositions and methods thereof for the treatment of cancer and other diseases |
AU2020204992A1 (en) | 2019-01-04 | 2021-07-15 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
SG11202107941TA (en) | 2019-01-23 | 2021-08-30 | Encefa | Cd31 competitors and uses thereof |
KR20210132117A (en) | 2019-02-26 | 2021-11-03 | 얀센 바이오테크 인코포레이티드 | Combination Therapy and Patient Stratification Using Bispecific Anti-EGFR/c-Met Antibodies |
EP3930847B1 (en) | 2019-02-26 | 2024-02-14 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
MX2021010288A (en) | 2019-03-01 | 2021-09-23 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof. |
AU2020231081A1 (en) | 2019-03-05 | 2021-09-30 | Prothena Biosciences Limited | Methods of treating AL amyloidosis |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
MA55529A (en) | 2019-04-03 | 2022-02-09 | Genzyme Corp | REDUCED FRAGMENTATION ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES |
GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
WO2020223565A1 (en) | 2019-05-01 | 2020-11-05 | Corvidia Therapeutics, Inc. | Anti-il-6 antibody formulation |
MX2021013766A (en) | 2019-05-14 | 2022-02-21 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof. |
JOP20210304A1 (en) | 2019-05-14 | 2023-01-30 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
MX2021015045A (en) | 2019-06-07 | 2022-03-17 | Amgen Inc | Bispecific binding constructs. |
MA56102A (en) | 2019-06-07 | 2022-04-13 | Argenx Bvba | PHARMACEUTICAL FORMULATIONS OF FCRN INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION |
EP3980064A1 (en) | 2019-06-10 | 2022-04-13 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
CN114174326A (en) | 2019-06-18 | 2022-03-11 | 拜耳公司 | Long-term stable adrenomedullin analogues and uses thereof |
EP3987010A1 (en) | 2019-06-21 | 2022-04-27 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
TW202120686A (en) | 2019-07-26 | 2021-06-01 | 美商舒爾人類基因療法公司 | Recombinant heme oxygenase-1 (ho-1) for the treatment of sickle cell disease |
CA3146471A1 (en) | 2019-08-06 | 2021-02-11 | James K. Kranz | Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders |
US20220242962A1 (en) | 2019-08-12 | 2022-08-04 | Aptevo Research And Development Llc | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40 |
WO2021030633A1 (en) | 2019-08-13 | 2021-02-18 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta agonists |
CN114585644A (en) | 2019-08-30 | 2022-06-03 | 艾吉纳斯公司 | anti-CD 96 antibodies and methods of use thereof |
TW202126284A (en) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | Lentiviral vector formulations |
WO2021094620A1 (en) | 2019-11-15 | 2021-05-20 | Enthera S.R.L. | Tmem219 antibodies and therapeutic uses thereof |
CN114746442A (en) | 2019-11-21 | 2022-07-12 | 恩瑟拉有限责任公司 | IGFBP3 antibodies and therapeutic uses thereof |
WO2021105389A1 (en) | 2019-11-29 | 2021-06-03 | Kymab Limited | Treatment for physiological iron overload |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
JP2023509195A (en) | 2020-01-08 | 2023-03-07 | アルジェニクス ビーブイ | How to treat pemphigus |
JP2023514152A (en) | 2020-02-06 | 2023-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | IL-10 and its uses |
EP3868396A1 (en) | 2020-02-20 | 2021-08-25 | Enthera S.R.L. | Inhibitors and uses thereof |
BR112022016999A2 (en) | 2020-02-28 | 2022-10-25 | Genzyme Corp | MODIFIED BINDING POLYPEPTIDES FOR OPTIMIZED DRUG CONJUGATION |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
US20230174626A1 (en) | 2020-03-27 | 2023-06-08 | Glaxosmithkline Biologicals Sa | Antibodies |
WO2021202463A1 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Anti-rsv antibodies |
TW202140543A (en) | 2020-04-20 | 2021-11-01 | 美商健臻公司 | Humanized anti-complement factor bb antibodies and uses thereof |
CN115605229A (en) | 2020-04-24 | 2023-01-13 | 米伦纽姆医药公司(Us) | anti-CD 19 antibodies and uses thereof |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
EP4153312A1 (en) | 2020-05-17 | 2023-03-29 | AstraZeneca UK Limited | Sars-cov-2 antibodies and methods of selecting and using the same |
KR20230015365A (en) | 2020-05-22 | 2023-01-31 | 포르미콘 아게 | ACE2 Fusion Proteins and Uses Thereof |
CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
WO2021251438A1 (en) | 2020-06-10 | 2021-12-16 | 株式会社バイカ・セラピュティクス | Fusion protein containing erythropoietin polypeptide |
CA3186143A1 (en) | 2020-06-17 | 2021-12-23 | Medimmune Limited | Heterodimeric relaxin fusions and uses thereof |
JP2023532266A (en) | 2020-06-23 | 2023-07-27 | ジアンスー カニョン ファーマシューティカル カンパニー リミテッド | Anti-CD38 antibody and use thereof |
KR20230023803A (en) * | 2020-06-23 | 2023-02-17 | 매든 어드바이저스 엘엘씨 | Anti-CCR5 monoclonal antibody-based compositions and methods |
WO2022006153A1 (en) | 2020-06-29 | 2022-01-06 | Resolve Therapeutics, Llc | Treatment of sjogren's syndrome with nuclease fusion proteins |
EP4175650A1 (en) | 2020-07-06 | 2023-05-10 | Kiromic BioPharma, Inc. | Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof |
AR122933A1 (en) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | METHODS TO TREAT CARDIOVASCULAR DISEASE |
KR20230044312A (en) | 2020-08-06 | 2023-04-03 | 바이오버라티브 유에스에이 인코포레이티드 | Inflammatory Cytokines and Fatigue in Subjects with Complement-Mediated Diseases |
BR112023002234A2 (en) | 2020-08-10 | 2023-03-07 | Astrazeneca Uk Ltd | SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19 |
AU2021328375A1 (en) | 2020-08-18 | 2023-04-13 | Cephalon Llc | Anti-PAR-2 antibodies and methods of use thereof |
WO2022050401A2 (en) | 2020-09-01 | 2022-03-10 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
KR20230084497A (en) | 2020-09-11 | 2023-06-13 | 메디뮨 리미티드 | Therapeutic B7-H4 binding molecules |
DE102020125457A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by HLA-A*02 molecules for use in immunotherapy against various types of cancer |
TW202229312A (en) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers |
DE102020125465A1 (en) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts presented by non-HLA-A*02 molecules for use in immunotherapy against various types of cancer |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
JP2023546359A (en) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy |
CR20230204A (en) * | 2020-10-14 | 2023-10-11 | Viridian Therapeutics Inc | Compositions and methods for treatment of thyroid eye disease |
US20240018499A1 (en) | 2020-10-29 | 2024-01-18 | Formycon Ag | ACE2 Fusion Proteins and Uses Thereof |
CA3202233A1 (en) | 2020-11-18 | 2022-05-27 | Kiromic BioPharma, Inc. | Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules |
WO2022119976A1 (en) | 2020-12-01 | 2022-06-09 | Aptevo Research And Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
JP2023553384A (en) | 2020-12-03 | 2023-12-21 | アムジエン・インコーポレーテツド | Immunoglobulin constructs with multiple binding domains |
US20240034814A1 (en) * | 2020-12-08 | 2024-02-01 | Janux Therapeutics, Inc. | Half-life extending compositions and methods |
CA3201588A1 (en) | 2020-12-09 | 2022-06-16 | David Campbell | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
CA3201818A1 (en) | 2020-12-11 | 2022-06-16 | Maria Fardis | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
EP4262811A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
JP2024500403A (en) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of cancer with tumor-infiltrating lymphocytes |
JP2023554456A (en) | 2020-12-18 | 2023-12-27 | チューハイ トリノマブ ファーマシューティカル カンパニー リミテッド | Molecule that specifically binds to respiratory syncytial virus |
TW202242085A (en) | 2020-12-31 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | Devices and processes for automated production of tumor infiltrating lymphocytes |
TW202241925A (en) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | Peptides displayed by hla for use in immunotherapy against different types of cancers |
CN117083297A (en) | 2021-01-22 | 2023-11-17 | 艾佩斯瑞生物制药公司 | anti-PD-L1 monoclonal antibodies and fusion proteins with interleukin-15 (IL-15), interleukin-15 receptor 15 alpha or interleukin-2 |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
TW202246324A (en) | 2021-03-01 | 2022-12-01 | 美商艾希利歐發展股份有限公司 | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
US20220306743A1 (en) | 2021-03-01 | 2022-09-29 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
AU2022230745A1 (en) | 2021-03-03 | 2023-08-17 | Formycon Ag | Formulations of ace2 fc fusion proteins |
JP2024509184A (en) | 2021-03-05 | 2024-02-29 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Tumor preservation and cell culture composition |
JP2024510505A (en) | 2021-03-19 | 2024-03-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Methods for tumor-infiltrating lymphocyte (TIL) expansion and gene knockout in TILs associated with CD39/CD69 selection |
JP2024511414A (en) | 2021-03-23 | 2024-03-13 | アイオバンス バイオセラピューティクス,インコーポレイテッド | CISH gene editing of tumor-infiltrating lymphocytes and its use in immunotherapy |
US20220313806A1 (en) | 2021-03-25 | 2022-10-06 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022207846A1 (en) | 2021-03-31 | 2022-10-06 | Cambridge Enterprise Limited | Therapeutic inhibitors of gdf15 signalling |
WO2022207785A1 (en) | 2021-03-31 | 2022-10-06 | Kymab Limited | Antibodies to gfral |
TW202304508A (en) | 2021-03-31 | 2023-02-01 | 美商百歐維拉提夫美國公司 | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
WO2022215054A1 (en) | 2021-04-09 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
IL307939A (en) | 2021-04-26 | 2023-12-01 | Millennium Pharm Inc | Anti-clec12a antibodies and uses thereof |
WO2022232035A1 (en) | 2021-04-26 | 2022-11-03 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
CN117396513A (en) | 2021-05-28 | 2024-01-12 | 葛兰素史密斯克莱知识产权发展有限公司 | Combination therapy for the treatment of cancer |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
AU2022295067A1 (en) | 2021-06-18 | 2023-12-21 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
CA3221555A1 (en) | 2021-06-23 | 2022-12-29 | Kimberly LONG | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
WO2023004074A2 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
CA3226942A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
TW202323822A (en) | 2021-08-03 | 2023-06-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | Biopharmaceutical compositions and stable isotope labeling peptide mapping method |
WO2023023503A1 (en) * | 2021-08-16 | 2023-02-23 | Yale University | Interleukin-12 variants and methods of use |
WO2023021169A1 (en) | 2021-08-20 | 2023-02-23 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
WO2023028501A1 (en) | 2021-08-23 | 2023-03-02 | Immunitas Therapeutics, Inc. | Anti-cd161 antibodies and uses thereof |
CN117881784A (en) | 2021-08-31 | 2024-04-12 | 大正制药株式会社 | Anti-growth hormone antibodies |
AU2022343729A1 (en) | 2021-09-09 | 2024-03-21 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
WO2023056362A1 (en) | 2021-09-30 | 2023-04-06 | Seagen Inc. | B7-h4 antibody-drug conjugates for the treatment of cancer |
CA3233953A1 (en) | 2021-10-05 | 2023-04-13 | Matthew Bruce | Combination therapies for treating cancer |
TW202330612A (en) | 2021-10-20 | 2023-08-01 | 日商武田藥品工業股份有限公司 | Compositions targeting bcma and methods of use thereof |
AR127482A1 (en) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023091968A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
WO2023111112A1 (en) | 2021-12-15 | 2023-06-22 | Medimmune Limited | Treatment using heterodimeric relaxin fusions |
WO2023114951A1 (en) | 2021-12-17 | 2023-06-22 | Viiv Healthcare Company | Combination therapies for hiv infections and uses thereof |
WO2023139107A1 (en) | 2022-01-18 | 2023-07-27 | argenx BV | Galectin-10 antibodies |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
TW202348252A (en) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | Combination therapies for treatment of cancer with therapeutic binding molecules |
US20230303719A1 (en) | 2022-03-03 | 2023-09-28 | Yale University | Humanized 3e10 antibodies, variants, and antigen binding fragments thereof |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023212304A1 (en) | 2022-04-29 | 2023-11-02 | 23Andme, Inc. | Antigen binding proteins |
WO2023213779A1 (en) | 2022-05-02 | 2023-11-09 | Novo Nordisk A/S | Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration |
WO2023220597A1 (en) | 2022-05-10 | 2023-11-16 | Elpis Biopharmaceuticals | Engineered interleukin-2 receptor beta reduced-binding agonist |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2023242361A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Fcrn binding molecules and methods of use |
WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
US20240034780A1 (en) | 2022-07-22 | 2024-02-01 | Flagship Pioneering Innovations Vi, Llc | Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP) |
WO2024026386A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibody formulations |
WO2024026395A1 (en) | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024026470A2 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024042112A1 (en) | 2022-08-25 | 2024-02-29 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins and uses thereof |
WO2024050421A2 (en) | 2022-08-30 | 2024-03-07 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting programmed cell death protein 1 (pd-1) |
US20240101691A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043713A1 (en) * | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
Family Cites Families (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
DE3668186D1 (en) | 1985-04-01 | 1990-02-15 | Celltech Ltd | TRANSFORMED MYELOMA CELL LINE AND METHOD USING THE SAME FOR EXPRESSING A GENE ENCODING AN EUKARYONTIC POLYPEPTIDE. |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
JP3095168B2 (en) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | Antibodies with domain-denaturing constants |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
KR900005995A (en) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | Modified Interleukin-2 and Method of Making the Same |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
EP0550436A1 (en) | 1989-11-06 | 1993-07-14 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
EP0521985B1 (en) | 1990-03-20 | 1997-09-24 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP2938569B2 (en) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | Method for producing xenogeneic immunoglobulin and transgenic mouse |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
WO1992006180A1 (en) | 1990-10-01 | 1992-04-16 | University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
ATE175118T1 (en) | 1990-10-05 | 1999-01-15 | Medarex Inc | TARGETED IMMUNOSTIMULATION WITH BISPECIFIC SUBSTANCES |
EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
KR100246529B1 (en) | 1990-12-14 | 2000-04-01 | 스티븐 에이. 서윈. 엠.디. | Chimeric chains for receptor-associated signal transduction pathways |
JPH05508779A (en) * | 1991-03-12 | 1993-12-09 | バイオジェン,インコーポレイテッド | CD2-binding domain of lymphocyte function-related antigen 3 |
JP3672306B2 (en) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | Heterodimeric receptor library using phagemids |
EP0511011B1 (en) | 1991-04-26 | 1996-10-23 | Surface Active Limited | Novel antibodies and methods for their use |
AU666852B2 (en) | 1991-05-01 | 1996-02-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
AU668870B2 (en) | 1991-05-14 | 1996-05-23 | Targetech, Inc | Targeted delivery of genes encoding immunogenic proteins |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1992022635A1 (en) | 1991-06-05 | 1992-12-23 | University Of Connecticut | Targeted delivery of genes encoding secretory proteins |
CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DK1024191T3 (en) | 1991-12-02 | 2008-12-08 | Medical Res Council | Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US20020102257A1 (en) | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
ATE239506T1 (en) | 1992-03-05 | 2003-05-15 | Univ Texas | USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND/OR THERAPY OF VASCULARIZED TUMORS |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5775745A (en) | 1992-06-09 | 1998-07-07 | Hoppe Holding Ag | Latch and lockset system |
JPH08501085A (en) | 1992-08-26 | 1996-02-06 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Use of cytokine IP-10 as an antitumor agent |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0671923B1 (en) | 1992-10-09 | 2001-04-18 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
EP1262564A3 (en) | 1993-01-07 | 2004-03-31 | Sequenom, Inc. | Dna sequencing by mass spectrometry |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
JPH09506262A (en) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | Method for producing specific antibody |
DK1231268T3 (en) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyclonal antibody libraries |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
JPH10511957A (en) | 1995-01-05 | 1998-11-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン | Surface-modified nanoparticles and methods for their production and use |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
WO1996022024A1 (en) | 1995-01-17 | 1996-07-25 | Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5916597A (en) | 1995-08-31 | 1999-06-29 | Alkermes Controlled Therapeutics, Inc. | Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
ATE279947T1 (en) * | 1996-03-18 | 2004-11-15 | Univ Texas | IMMUNOGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-LIFE TIMES |
CA2248868A1 (en) | 1996-03-22 | 1997-09-25 | Human Genome Sciences, Inc. | Apoptosis inducing molecule ii |
WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
ES2301183T3 (en) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | COMPLETELY HUMAN ANTIBODY THAT JOINS THE EGFR RECEIVER. |
ES2236832T3 (en) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | PREPARATION OF PARTICLES FOR INHALATION. |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
SI0970126T1 (en) | 1997-04-14 | 2001-08-31 | Micromet Ag | Novel method for the production of antihuman antigen receptors and uses thereof |
JP4213224B2 (en) * | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | Method for producing multispecific antibody having heteromultimer and common component |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6133166A (en) | 1997-07-01 | 2000-10-17 | The Procter & Gamble Company | Cleaning articles comprising a cellulosic fibrous structure having discrete basis weight regions treated with a high internal phase inverse emulsion |
US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (en) | 1997-10-23 | 2000-04-17 | Biogram Ab | Active substance encapsulation process in a biodegradable polymer |
CN1174993C (en) | 1997-11-03 | 2004-11-10 | 人体基因组科学有限公司 | VEGI, an inhibitor of angiogenesis and tumor growth |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2198922T3 (en) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | LARGE POROUS PARTICLES ISSUED BY AN INHALER. |
US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
AU785038B2 (en) | 2000-01-27 | 2006-08-31 | Applied Molecular Evolution, Inc. | Ultra high affinity neutralizing antibodies |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
JP5179689B2 (en) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Enhancing the half-life of antibody-based fusion proteins in the circulation |
EP2341074A1 (en) * | 2000-03-01 | 2011-07-06 | MedImmune, LLC | Antibodies binding to the f protein of a respiratory syncytial virus (rsv) |
AU5345901A (en) | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
US6818216B2 (en) * | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US6855493B2 (en) * | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
CA2444680A1 (en) | 2001-04-18 | 2002-10-31 | Dyax Corp. | Binding molecules for fc-region polypeptides |
US6911321B2 (en) | 2001-12-19 | 2005-06-28 | Genentech, Inc. | Non-human primate Fc receptors and methods of use |
US7219797B2 (en) * | 2002-01-14 | 2007-05-22 | Alliance Packaging Llc. | Box with insert that extends from a side and that divides the box into compartments and methods for forming and using |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
DK1562972T3 (en) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modification of FcRn binding affinities or serum half-lives for antibodies by mutagenesis |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7217798B2 (en) * | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US7365168B2 (en) * | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1812068A4 (en) * | 2004-10-29 | 2010-06-09 | Medimmune Inc | Methods of preventing and treating rsv infections and related conditions |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
EP2373689A1 (en) | 2008-12-12 | 2011-10-12 | MedImmune, LLC | Crystals and structure of a human igg fc variant with enhanced fcrn binding |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
-
2001
- 2001-12-12 EP EP10010679.8A patent/EP2341060B1/en not_active Expired - Lifetime
- 2001-12-12 EP EP10010681A patent/EP2357187A1/en not_active Withdrawn
- 2001-12-12 AU AU2002248184A patent/AU2002248184C1/en not_active Expired
- 2001-12-12 WO PCT/US2001/048432 patent/WO2002060919A2/en active Search and Examination
- 2001-12-12 AT AT01997063T patent/ATE489395T1/en active
- 2001-12-12 US US10/020,354 patent/US7083784B2/en not_active Expired - Lifetime
- 2001-12-12 DE DE60143544T patent/DE60143544D1/en not_active Expired - Lifetime
- 2001-12-12 CA CA2431600A patent/CA2431600C/en not_active Expired - Lifetime
- 2001-12-12 DK DK01997063.1T patent/DK1355919T3/en active
- 2001-12-12 ES ES10010679T patent/ES2727425T3/en not_active Expired - Lifetime
- 2001-12-12 ES ES10010680.6T patent/ES2649037T3/en not_active Expired - Lifetime
- 2001-12-12 PT PT01997063T patent/PT1355919E/en unknown
- 2001-12-12 JP JP2002561487A patent/JP4336498B2/en not_active Expired - Lifetime
- 2001-12-12 EP EP19153658.0A patent/EP3569610A3/en not_active Withdrawn
- 2001-12-12 EP EP01997063A patent/EP1355919B1/en not_active Expired - Lifetime
- 2001-12-12 EP EP10010680.6A patent/EP2354149B1/en not_active Expired - Lifetime
-
2006
- 2006-04-03 US US11/397,328 patent/US7670600B2/en not_active Expired - Lifetime
-
2007
- 2007-01-03 US US11/649,455 patent/US7704497B2/en not_active Expired - Lifetime
- 2007-08-27 JP JP2007219930A patent/JP4336376B2/en not_active Expired - Lifetime
-
2009
- 2009-05-08 JP JP2009113588A patent/JP5265446B2/en not_active Expired - Lifetime
-
2010
- 2010-01-04 JP JP2010000073A patent/JP5444010B2/en not_active Expired - Lifetime
- 2010-01-21 US US12/691,433 patent/US8012476B2/en not_active Expired - Fee Related
-
2011
- 2011-02-24 CY CY20111100229T patent/CY1111283T1/en unknown
- 2011-07-27 US US13/192,429 patent/US8323962B2/en not_active Expired - Lifetime
-
2012
- 2012-10-24 US US13/659,144 patent/US8475792B2/en not_active Expired - Lifetime
-
2013
- 2013-05-20 US US13/898,042 patent/US8795661B2/en not_active Expired - Fee Related
- 2013-08-16 JP JP2013169026A patent/JP6125949B2/en not_active Expired - Lifetime
-
2014
- 2014-06-20 US US14/310,507 patent/US9562100B2/en not_active Expired - Lifetime
-
2015
- 2015-07-13 JP JP2015139342A patent/JP6268127B2/en not_active Expired - Lifetime
-
2016
- 2016-12-21 JP JP2016247406A patent/JP2017079771A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043713A1 (en) * | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8734791B2 (en) | 2002-03-01 | 2014-05-27 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US9193798B2 (en) | 2002-09-27 | 2015-11-24 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8093359B2 (en) | 2002-09-27 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8858937B2 (en) | 2002-09-27 | 2014-10-14 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8383109B2 (en) | 2002-09-27 | 2013-02-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9353187B2 (en) | 2002-09-27 | 2016-05-31 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US8809503B2 (en) | 2002-09-27 | 2014-08-19 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8937158B2 (en) | 2003-03-03 | 2015-01-20 | Xencor, Inc. | Fc variants with increased affinity for FcγRIIc |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8735545B2 (en) | 2003-03-03 | 2014-05-27 | Xencor, Inc. | Fc variants having increased affinity for fcyrllc |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8338574B2 (en) | 2004-11-12 | 2012-12-25 | Xencor, Inc. | FC variants with altered binding to FCRN |
US8324351B2 (en) | 2004-11-12 | 2012-12-04 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US9574006B2 (en) | 2005-10-06 | 2017-02-21 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002060919A3 (en) | Molecules with extended half-lives, compositions and uses thereof | |
AT500379B1 (en) | TAU PROTEINS | |
DK1135498T3 (en) | Antibody variants with higher binding affinity than parental antibodies | |
BR0314093A (en) | Modified transferrin-antibody fusion proteins | |
DE69807679D1 (en) | COMPOSITIONS OF CONJUGATES OF THE STABLE, ACTIVE, HUMAN OB PROTEINS WITH THE FC CHAIN OF IMMUNOGLOBULINES AND RELATED PROCEDURES | |
BR9916853A (en) | Human monoclonal antibodies to ctla-4 | |
WO2003070760A3 (en) | Anti-amyloid beta antibodies and their use | |
WO2000078344A8 (en) | Prion protein peptides and uses thereof | |
WO2002074337A8 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
NZ596865A (en) | Single-chain multivalent binding proteins with effector function | |
WO2002020569A3 (en) | Mammalian genes; related reagents and methods | |
UA89017C2 (en) | HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO hTNFSF13B | |
WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
WO2006083964A3 (en) | Modified fusion molecules for treatment of allergic disease | |
ES2098274T3 (en) | MONOCLONAL ANTIBODIES. | |
AU5874999A (en) | Immunoglobulin binding protein | |
WO2001057219A3 (en) | Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods | |
WO2001007479A3 (en) | Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases | |
WO2004100882A3 (en) | Inhibition of drug binding to serum albumin | |
WO2002020614A3 (en) | Endoglin-specific polypeptide, production and use thereof | |
WO2001012806A3 (en) | Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof | |
WO2003014344A3 (en) | Expression of modified antibodies in avian cells | |
WO2001090156A3 (en) | Card domain containing polypeptides, encoding nucleic acids, and methods of use | |
WO2003033675A3 (en) | Identification of binding partners for specific proteins | |
WO2005000896A3 (en) | Polypeptides that bind an anti-tissue factor antibody and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/11-11/11, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002561487 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2431600 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002248184 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001997063 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001997063 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2002248184 Country of ref document: AU Date of ref document: 20011212 Kind code of ref document: B |